CONSORT diagram for study design and patient disposition. (*) Increased ALT/AST (n = 1 patient) and pneumonitis (n = 1 patient). (†) Increased ALT/AST (n = 3 patients); colitis (n = 2 patients); diarrhea (n = 2 patients); colitis, cystitis, and transaminitis (n = 1 patient); and diarrhea and hyperthyroidism (n = 1 patient). (‡) Acute renal failure, autoimmune hepatitis, diarrhea, enteritis, increased ALT/AST, lymphocytic myocarditis, and pneumonitis (n = 1 patient each). AE, adverse event; IPI1, ipilimumab 1 mg/kg; IPI3, ipilimumab 3 mg/kg; NIVO1, nivolumab 1 mg/kg; NIVO3, nivolumab 3 mg/kg.